Table 3.
Lung function
| Treatment | FPSM | FPSM/FP | FPSM/BDP | FPSM/PRED |
|---|---|---|---|---|
| Spirometry | ||||
| FEV1 (l) | 2.16 (1.81 to 2.51) | 2.18 (1.82 to 2.54) | 2.21 (1.81 to 2.61) | 2.26 (1.89 to 2.63) |
| FEF25–75 (l) | 1.35 (0.98 to 1.71) | 1.29 (0.92 to 1.66) | 1.36 (0.95 to 1.77) | 1.38 (1.00 to 1.76) |
| FVC (l) | 3.42 (3.03 to 3.81) | 3.40 (3.00 to 3.81) | 3.45 (3.03 to 3.87) | 3.49 (3.08 to 3.90) |
| RVC (l) | 3.70 (3.25 to 4.16) | 3.49 (3.03 to 3.94} | 3.51 (3.06 to 3.96) | 3.66 (3.26 to 4.06) |
| FEV1 (%) | 63.4 (57.6 to 69.1) | 64.2 (59.0 to 69.4) | 64.6 (58.5 to 70.7) | 65.5 (59.6 to 71.4) |
| FEF25–75 (%) | 34.8 (26.3 to 43.3) | 34.0 (25.4 to 42.5) | 35.0 (25.7 to 44.3) | 35.6 (26.6 to 44.6) |
| FVC (%) | 83.2 (78.5 to 88.0) | 83.0 (80.4 to 85.6) | 83.9 (81.2 to 86.7) | 83.6 (78.5 to 88.7) |
| RVC (%0 | 88.0 (83.5 to 92.5) | 82.5 (77.9 to 87.0) | 82.6 (79.2 to 86.0) | 84.8 (81.3 to 88.4) |
| Impulse oscillometry | ||||
| R5 (kPa l−1 s) | 0.47 (0.39 to 0.56) | 0.45 (0.40 to 0.59) | 0.44 (0.41 to 0.66) | 0.47 (0.37 to 0.68 |
| R5-R20 | 0.13 (0.23 to 0.13) | 0.11 (0.06 to 0.23) | 0.11 (0.06 to 0.25) | 0.09 (0.03 to 0.21) |
| X5 (kPa l−1 s) | −0.15 (−0.23 to −0.13) | −0.17 (−0.24 to −0.13) | −0.15 (−0.26 to −0.12) | −0.15 (−0.33 to −0.12) |
| Body plethysmography | ||||
| sRaw (kPa s−1) | 1.87 (1.31 to 2.42) | 1.94 (1.43 to 2.45) | 2.02 (1.51 to 2.54) | 1.57 (1.02 to 2.13) |
| sRaw (%) | 166 (114 to 218) | 175 (127 to 222) | 180 (131 to 229) | 142 (93 to 192) |
| RV (l) | 3.28 (2.58 to 3.97) | 3.16 (2.80 to 3.51) | 3.44 (2.60 to 4.28) | 2.76 (2.42 to 3.10) |
| RV (%) | 159 (113 to 205) | 144 (127 to 161) | 170 (113 to 227) | 130 (117 to 143) |
| RV/TLC | 0.44 (0.38 to 0.51) | 0.46 (0.41 to 0.50) | 0.46 (0.41 to 0.52) | 0.41 (0.36 to 0.46) |
Presented as mean and (95% CI) except impulse oscillometry which is median (IQR). % shown as percent predicted for race, age and gender. FP, fluticasone; FPSM, fluticasone/salmeterol; BDP, beclomethasone diproprionate; PRED, prednisolone.